A recent case report highlights the connection between anemia and celiac disease, emphasizing the need for thorough investigation in patients presenting with anemia. This finding could lead to improved diagnosis and management of celiac disease.

First Tracks reports promising initial findings from a study targeting the CD122 protein, enhancing analysts' confidence in its potential as a 'pipeline-in-a-product.' This development could significantly impact treatment options for celiac disease.

Argenx faces a setback as a monitoring board recommends halting the Sjögren’s syndrome study for futility, impacting its growth prospects. This decision overshadows progress made with its celiac disease treatment, Vyvgart.

A recent study highlights celiac disease presenting as fever of unknown origin, complicating diagnosis. This research underscores the need for awareness among clinicians regarding atypical manifestations of celiac disease.

Teva reports success in a celiac disease study, highlighting the therapy's potential as a 'pipeline-in-a-product.' Meanwhile, BioMarin and Ascendis have settled a patent dispute, which may impact their respective product developments.